Patiromer-Facilitated Renin-Angiotensin-Aldosterone System Inhibitor Utilization in Patients with Heart Failure with or without Comorbid Chronic Kidney Disease: Subgroup Analysis of DIAMOND Randomized Trial
American Journal of Nephrology · 2024
DOI: 10.1159/000540453 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Nephrology, 2024. Verfasst von Matthew R Weir und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Heart Failure, Renal Insufficiency, Chronic, Renin-Angiotensin System, Mineralocorticoid Receptor Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Introduction
Renin-angiotensin-aldosterone system inhibitor (RAASi; including mineralocorticoid receptor antagonists [MRAs]) benefits are greatest in patients with heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD); however, the risk of hyperkalemia (HK) is high.
Methods
The DIAMOND trial (NCT03888066) assessed the ability of patiromer to control serum potassium (sK+) in patients with HFrEF with/without CKD. Prior to randomization (double-blind withdrawal, 1:1), patients on patiromer had to achieve ≥50% recommended doses of RAASi and 50 mg/day of MRA with normokalemia during a run-in period. The present analysis assessed the effect of baseline estimated glomerular filtration rate (eGFR) in subgroups of ≥/<60, ≥/<45 (prespecified), and ≥/<30 mL/min/1.73 m2 (added post hoc).
Results
In total, 81.3, 78.9, and 81.1% of patients with eGFR <60, <45, and <30 mL/min/1.73 m2 at screening achieved RAASi/MRA targets. A greater efficacy of patiromer versus placebo to control sK+ in patients with more advanced CKD was reported (p-interaction ≤ 0.027 for all eGFR subgroups). Greater effects on secondary endpoints were observed with patiromer versus placebo in patients with eGFR <60 and <45 mL/min/1.73 m2. Adverse effects were similar between patiromer and placebo across subgroups.
Conclusion
Patiromer enabled use of RAASi, controlled sK+, and minimized HK risk in patients with HFrEF, with greater effect sizes for most endpoints noted in patient subgroups with lower eGFR. Patiromer was well tolerated by patients in all eGFR subgroups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
- INSERM CIC-P 1433, CHRU de Nancy, INSERM U1116, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Université de Lorraine, Nancy, France.
- Department of Medical Specialties and Nephrology-Hemodialysis, Princess Grace Hospital, Centre d'Hémodialyse Privé de Monaco, Monaco, Monaco.
- Division of Cardiology, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Medicine, Unit of Cardiology, Karolinska Institutet, Solna, Sweden.
- Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
Zitieren
APA
Weir, M. R., Rossignol, P., Pitt, B., Lund, L. H., Coats, A. J. S., Filippatos, G., Perrin, A., Waechter, S., Budden, J., Kosiborod, M., Metra, M., Boehm, M., Ezekowitz, J. A., Bayes-Genis, A., Mentz, R. J., Ponikowski, P., Senni, M., Castro-Montes, E., Nicolau, J. C., …, & Butler, J. (2024). Patiromer-Facilitated Renin-Angiotensin-Aldosterone System Inhibitor Utilization in Patients with Heart Failure with or without Comorbid Chronic Kidney Disease: Subgroup Analysis of DIAMOND Randomized Trial. American Journal of Nephrology. https://doi.org/10.1159/000540453
Vancouver
Weir MR, Rossignol P, Pitt B, Lund LH, Coats AJS, Filippatos G, et al. Patiromer-Facilitated Renin-Angiotensin-Aldosterone System Inhibitor Utilization in Patients with Heart Failure with or without Comorbid Chronic Kidney Disease: Subgroup Analysis of DIAMOND Randomized Trial. American Journal of Nephrology. 2024. doi:10.1159/000540453
BibTeX
@article{Weir2024,
author = {Weir, Matthew R and Rossignol, Patrick and Pitt, Bertram and Lund, Lars H and Coats, Andrew J S and Filippatos, Gerasimos and Perrin, Amandine and Waechter, Sandra and Budden, Jeffrey and Kosiborod, Mikhail and Metra, Marco and Boehm, Michael and Ezekowitz, Justin A and Bayes-Genis, Antoni and Mentz, Robert J and Ponikowski, Piotr and Senni, Michele and Castro-Montes, Eliodoro and Nicolau, Jose Carlos and Parkhomenko, Alexandr and Seferovic, Petar and Cohen-Solal, Alain and Anker, Stefan D and Butler, Javed},
title = {Patiromer-Facilitated Renin-Angiotensin-Aldosterone System Inhibitor Utilization in Patients with Heart Failure with or without Comorbid Chronic Kidney Disease: Subgroup Analysis of DIAMOND Randomized Trial},
journal = {American Journal of Nephrology},
year = {2024},
doi = {10.1159/000540453}
}
EUVIMED